Methotrexate inhibits the viability of human melanoma cell lines and enhances Fas/Fas-ligand expression, apoptosis and response to interferon-alpha: Rationale for its use in combination therapy

Archives of Biochemistry and Biophysics

Volumn 563, Issue , 2014, Pages 101-107

  Nihal, Minakshi ^a,b   Wu, Jianqiang ^a   Wood, Gary S ^a,b,c  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN   (United States)

^c Wm S Middleton VA Medical Centre   (United States)

Author keywords

Apoptosis; DNA methylation; Fas FasL; Melanoma; Methotrexate

Indexed keywords

ALPHA2B INTERFERON; BETA GALACTOSIDASE; CASPASE 8; CASPASE 9; FAS ANTIGEN; FAS LIGAND; LIPOCORTIN 5; METHOTREXATE; ALPHA INTERFERON; FAS PROTEIN, HUMAN; FASLG PROTEIN, HUMAN; RECOMBINANT PROTEIN;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL VIABILITY; DNA METHYLATION; DRUG POTENTIATION; ENZYME ACTIVITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; MELANOMA; MELANOMA CELL LINE; PROTEIN EXPRESSION; PYROSEQUENCING; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; CELL AGING; CELL SURVIVAL; DRUG COMBINATION; DRUG EFFECTS; GENETICS; METABOLISM; PATHOLOGY; PROMOTER REGION; TUMOR CELL LINE;

ANTIGENS, CD95; APOPTOSIS; CELL AGING; CELL LINE, TUMOR; CELL SURVIVAL; DNA METHYLATION; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FAS LIGAND PROTEIN; HUMANS; INTERFERON-ALPHA; MELANOMA; METHOTREXATE; PROMOTER REGIONS, GENETIC; RECOMBINANT PROTEINS;

EID: 84908394294     PISSN: 00039861     EISSN: 10960384     Source Type: Journal    
DOI: 10.1016/j.abb.2014.04.019     Document Type: Article

References (40)

1. R. Kainthla, K.B. Kim, and G.S. Falchook Pharmgenomics Pers. Med. 7 2014 21 29
2. S. Jang, and M.B. Atkins Lancet Oncol. 14 2013 e60 e69
3. S. Jang, and M.B. Atkins Clin. Pharmacol. Ther. 95 2014 24 31
4. M. Camargo, and J. Cervenka Hum. Genet 54 1980 47 53
5. M. Martin, A. Villar, A. Sole-Calvo, R. Gonzalez, B. Massuti, J. Lizon, C. Camps, A. Carrato, A. Casado, M.T. Candel, J. Albanell, J. Aranda, B. Munarriz, J. Campbell, and E. Diaz-Rubio Ann. Oncol. 14 2003 833 842
6. S. Richards, C.H. Pui, and P. Gayon Pediatr. Blood Cancer 60 2013 185 195
7. K. Takahashi, S. Tsukamoto, K. Saito, N. Ohkohchi, and K. Hirayama World J. Gastroenterol. 19 2013 5187 5194
8. L. Porcelli, Y.G. Assaraf, A. Azzariti, A. Paradiso, G. Jansen, and G.J. Peters Curr. Drug Metab. 12 2011 975 984
9. K.B. Kim, F.R. Khuri, and D.M. Shin Expert Rev. Anticancer Ther. 1 2001 99 110
10. J.B. Sorensen, and H.H. Hansen Cancer Chemother. Pharmacol. 21 1988 103 116
11. C. Friesen, I. Herr, P.H. Krammer, and K.M. Debatin Nat. Med. 2 1996 574 577
12. J. O'Connell, G.C. O'Sullivan, J.K. Collins, and F. Shanahan J. Exp. Med. 184 1996 1075 1082
13. M. Hahne, D. Rimoldi, M. Schroter, P. Romero, M. Schreier, L.E. French, P. Schneider, T. Bornand, A. Fontana, D. Lienard, J. Cerottini, and J. Tschopp Science 274 1996 1363 1366
14. L.B. Owen-Schaub, K.L. van Golen, L.L. Hill, and J.E. Price J. Exp. Med. 188 1998 1717 1723
15. H. Chan, D.P. Bartos, and L.B. Owen-Schaub Mol. Cell Biol. 19 1999 2098 2108
16. R.R. Bullani, P. Wehrli, I. Viard-Leveugle, D. Rimoldi, J.C. Cerottini, J.H. Saurat, J. Tschopp, and L.E. French Melanoma Res. 12 2002 263 270
17. V.N. Ivanov, A. Bhoumik, and Z. Ronai Oncogene 22 2003 3152 3161
18. S. Ugurel, S. Seiter, G. Rappl, A. Stark, W. Tilgen, and U. Reinhold Int. J. Cancer 82 1999 727 736
19. H. Helmbach, E. Rossmann, M.A. Kern, and D. Schadendorf Int. J. Cancer 93 2001 617 622
20. S. Ekmekcioglu, M.F. Okcu, M.I. Colome-Grimmer, L. Owen-Schaub, A.C. Buzaid, and E.A. Grimm Melanoma Res. 9 1999 261 272
21. J. Wu, and G.S. Wood Arch. Dermatol. 147 2011 443 449
22. J. Wu, J. Siddiqui, M. Nihal, E.C. Vonderheid, and G.S. Wood Arch. Biochem. Biophys. 508 2011 185 191
23. C.A. Barker, and M.A. Postow Int. J. Radiat. Oncol. Biol. Phys. 88 2014 986 997
24. M. Voskoboynik, and H.T. Arkenau Biochem. Res. Int. 2014 2014 307059
25. J. Wu, M. Nihal, J. Siddiqui, E.C. Vonderheid, and G.S. Wood J. Invest. Dermatol. 129 2009 1165 1173
26. M.R. Philips, Sci. STKE 2004 (2004) pe13.
27. M. Saez-Ayala, M.P. Fernandez-Perez, M.F. Montenegro, L. Sanchez-del-Campo, S. Chazarra, A. Pinero-Madrona, J. Cabezas-Herrera, and J.N. Rodriguez-Lopez Exp. Cell Res. 318 2012 1146 1159
28. L. Sanchez-del-Campo, M.F. Montenegro, J. Cabezas-Herrera, and J.N. Rodriguez-Lopez Pigment Cell Melanoma Res. 22 2009 588 600
29. R.T. Schimke Cell 37 1984 705 713
30. M. Rothenberg, and V. Ling J. Natl. Cancer Inst. 81 1989 907 910
31. S. Ugurel, G. Rappl, W. Tilgen, and U. Reinhold Clin. Cancer Res. 7 2001 1282 1286
32. A. Aviles, M.J. Nambo, N. Neri, C. Castaneda, S. Cleto, M. Gonzalez, and J. Huerta-Guzman Cancer Biother. Radiopharm. 22 2007 836 840
33. G. Porcile, M. Musso, F. Boccardo, R. Rosso, and L. Santi Tumori 65 1979 237 240
34. A.K. Sinha, S. Anand, B.J. Ortel, Y. Chang, Z. Mai, T. Hasan, and E.V. Maytin Br. J. Cancer 95 2006 485 495
35. L. Sanchez-del-Campo, S. Chazarra, M.F. Montenegro, J. Cabezas-Herrera, and J.N. Rodriguez-Lopez J. Cell Biochem. 110 2010 1399 1409
36. L. Sanchez-del-Campo, and J.N. Rodriguez-Lopez Int. J. Cancer 123 2008 2446 2455
37. L. Sanchez-del-Campo, A. Tarraga, M.F. Montenegro, J. Cabezas-Herrera, and J.N. Rodriguez-Lopez Mol. Pharm. 6 2009 883 894
38. M. Saez-Ayala, M.F. Montenegro, L. Sanchez-Del-Campo, M.P. Fernandez-Perez, S. Chazarra, R. Freter, M. Middleton, A. Pinero-Madrona, J. Cabezas-Herrera, C.R. Goding, and J.N. Rodriguez-Lopez Cancer Cell 24 2013 105 119
39. J. Wu, and G.S. Wood J. Invest. Dermatol. 134 2014 S32
40. K.A. Salva, M. Nihal, J. Wu, and G.S. Wood J. Invest. Dermatol. 134 2014 S117